ABVX

$ABVX chatter on StockTwits

• 
  alex pitti@alexpitti29m

  i bought $ABVX sold $MIST i lost money on $ABEO and $STXS i made money?????? on $DCTH

  View on StockTwits ↗
• 
  Jacob Berkstein@Jacob_Berkstein44m

  $SLS the $ABVX $5 to $148 run will look Anemic compared to whats about to happen Here... ANY DAY. SLS is about to announce phase 3 registrational trial results, 6+ years in the making, giving GPs the Fda green light to treat upwards of 50,000 AML Remission Patients each year - and Generate TENS of BILLIONS of dollars in Real Revenue - that is worth every nickel of $50B to big pharm. Do the Math + 2X 3X 4X survival advantage for CR2/3 Patients, combined w: • GPS Pristine Safety Profile • Prior Phase 2 Results in CR1 that are Better than Transplant • EAP for CR1 and post Transplant Patients REQUIRE Gps Value include the CR1 / Post Transplant Market. 100,000 Patients currently in remission who'll benefit from GPS right out of the Gate. • FDA Already signed off on TypeC Manufacture, low cost/high margin • FDA/EU Orphan / Fast Track / Rare Priority Review • IP rights into 2037 + Next Gen GPS+ Immunotherapy • Ease of administration, in home will Set Records for Patient Uptake Rates.

  View on StockTwits ↗
• 
  Peter O.@frontiereBullish1h

  $ABVX Abivax ref=$119 — Long adding today — most properly done deals are in confidentiality and thus charts often slide down into a surprise spike of deal announcement. As just one example of many, look up $TRIL Trillium bought out by PFE end of Aug 2021. I am NOT guaranteeing that this is the scenario here, BUT just relying on pretty frequent experience to say that as long as a priori thesis stands (bullish Obe) then the price decline and buyer exhaustion is “normal”. IF… https://www.investing.com/equities/stem-cell-therapeutics-corp.-advanced-chart

  View on StockTwits ↗
• 
  alex pitti@alexpitti2h

  I replaced my $MIST with my $ABVX i think that abivax can get a buyout within 9 months. i think milestone needs to accelerates scripts which is hard when docs are forgetting about it, it takes long to hear back from patients, coverage is a mixed bag requiring prior auths. unh is trying to only allow people who have been to the er first. they will sell you dead for a penny

  View on StockTwits ↗
• 
  Monkey Banana Genius Forever@MonkeyBananaGenius4h

  @simon58 Yep that's one of them. Jut added to $ABVX at 119.

  View on StockTwits ↗
• 
  5,500% ROI this quarter@55X_ROI_Q1_20265h

  $SLS the $ABVX $5 to $148 run will look Anemic compared to whats about to happen Here... ANY DAY. SLS is about to announce phase 3 registrational trial results, 6+ years in the making, giving GPs the Fda green light to treat upwards of 50,000 AML Remission Patients each year - and Generate TENS of BILLIONS of dollars in Real Revenue - that is worth every nickel of $50B to big pharm. Do the Math + 2X 3X 4X survival advantage for CR2/3 Patients, combined w: • GPS Pristine Safety Profile • Prior Phase 2 Results in CR1 that are Better than Transplant • EAP for CR1 and post Transplant Patients REQUIRE Gps Value include the CR1 / Post Transplant Market. 100,000 Patients currently in remission who'll benefit from GPS right out of the Gate. • FDA Already signed off on TypeC Manufacture, low cost/high margin • FDA/EU Orphan / Fast Track / Rare Priority Review • IP rights into 2037 + Next Gen GPS+ Immunotherapy • Ease of administration, in home will Set Records for Patient Uptake Rates.

  View on StockTwits ↗
• 
  alex pitti@alexpitti19h

  i believe $ABVX will sell itself in q1 2027 for $190 per share

  View on StockTwits ↗
• 
  X@Fairvalue1019h

  $ABVX Stay patient. Recent price action is noise. US volumes are too thin to be meaningful. With ~95% of the float held by institutions sitting tight ahead of the catalyst, the effective free float is minimal and it takes very little size to mark the stock lower. European liquidity is even thinner, essentially non-existent. Nothing here changes the thesis.

  View on StockTwits ↗
• 
  alex pitti@alexpitti21h

  I'm a massive believer in $ABVX

  View on StockTwits ↗
• 
  Tony M@SellasgpsCurativeBAT11Bullish1d

  $ABVX $CDTX $RVMD $SLS Why am I sharing this with my fellow Sellas Brothers and Sisters? Because shorts try to create a doubt in your heads and “Doubt kills more dreams everyday than failure ever will” Hold with Conviction and stay strong 💪 ✌️🙏❤️‍🩹

  View on StockTwits ↗
• 
  Easy E@EddieH20201d

  $ABVX The ABVX guys on Twitter make this stock seem so terrible what a shame

  View on StockTwits ↗
• 
  Tony M@SellasgpsCurativeBAT11Bullish1d

  $ABVX $CDTX $RVMD $SLS A picture is worth a thousand words $CDTX was my biggest hit of all time. I started buying $CDTX a little over $2.13 after watching the ticker passing by on CNBC a few years ago.👇 Merck completed its acquisition of Cidara Therapeutics (NASDAQ: CDTX) on January 7, 2026, buying the biotechnology company for $221.50 per share in cash. The total transaction value was approximately $9.2 billion. Hold with Conviction because opportunities like this come very rarely. Don’t step over a hundred dollar 💵 Bills to pick up Pennie’s.👇 ✌️🙏❤️‍🩹

  View on StockTwits ↗
• 
  Buy and Sold@buyandsold1d

  $ABVX they have filed for a new ticker GIA

  View on StockTwits ↗
• 
  Geoff Weiss@AceInTheHole18Bullish1d

  $ABVX need a win! LFG

  View on StockTwits ↗
• 
  Machiavel@MachiaveltradeBullish1d

  $ABVX just be ready for the good time

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.